DK3728271T3 - Makrocykliske forbindelser til behandling af sygdomme - Google Patents
Makrocykliske forbindelser til behandling af sygdomme Download PDFInfo
- Publication number
- DK3728271T3 DK3728271T3 DK18893293.3T DK18893293T DK3728271T3 DK 3728271 T3 DK3728271 T3 DK 3728271T3 DK 18893293 T DK18893293 T DK 18893293T DK 3728271 T3 DK3728271 T3 DK 3728271T3
- Authority
- DK
- Denmark
- Prior art keywords
- diseases
- treatment
- macrocyclic compounds
- macrocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607528P | 2017-12-19 | 2017-12-19 | |
| US201862727124P | 2018-09-05 | 2018-09-05 | |
| US201862779283P | 2018-12-13 | 2018-12-13 | |
| PCT/US2018/066158 WO2019126121A1 (en) | 2017-12-19 | 2018-12-18 | Macrocyclic compounds for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3728271T3 true DK3728271T3 (da) | 2022-12-19 |
Family
ID=66992951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18893293.3T DK3728271T3 (da) | 2017-12-19 | 2018-12-18 | Makrocykliske forbindelser til behandling af sygdomme |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10745416B2 (da) |
| EP (2) | EP4151641A1 (da) |
| JP (2) | JP7194188B2 (da) |
| KR (1) | KR102814342B1 (da) |
| CN (1) | CN111511746B (da) |
| AU (1) | AU2018392332B2 (da) |
| BR (1) | BR112020012319A2 (da) |
| CA (1) | CA3083674A1 (da) |
| CL (1) | CL2020001632A1 (da) |
| DK (1) | DK3728271T3 (da) |
| EC (1) | ECSP20033467A (da) |
| ES (1) | ES2929467T3 (da) |
| HR (1) | HRP20221502T1 (da) |
| HU (1) | HUE060711T2 (da) |
| IL (1) | IL275265B2 (da) |
| JO (1) | JOP20200152A1 (da) |
| LT (1) | LT3728271T (da) |
| MX (1) | MX2020006490A (da) |
| PE (1) | PE20200937A1 (da) |
| PH (1) | PH12020550901A1 (da) |
| PL (1) | PL3728271T3 (da) |
| PT (1) | PT3728271T (da) |
| RS (1) | RS63787B1 (da) |
| SG (1) | SG11202005590PA (da) |
| SI (1) | SI3728271T1 (da) |
| SM (1) | SMT202200443T1 (da) |
| TW (1) | TW201930312A (da) |
| WO (1) | WO2019126121A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4331585A3 (en) | 2015-11-02 | 2024-05-15 | Blueprint Medicines Corporation | Inhibitors of ret |
| SMT202100656T1 (it) | 2017-10-18 | 2022-01-10 | Incyte Corp | Derivati di imidazolo condensati sostituiti con gruppi ossidrile terziari come inibitori di pi3k-gamma |
| PE20200937A1 (es) | 2017-12-19 | 2020-09-17 | Turning Point Therapeutics Inc | Compuestos macrociclicos para tratar enfermedades |
| HRP20211918T8 (hr) | 2017-12-19 | 2022-04-15 | Bristol-Myers Squibb Company | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti |
| ES2970041T3 (es) | 2018-04-03 | 2024-05-24 | Blueprint Medicines Corp | Inhibidor de RET para su uso en el tratamiento del cáncer que tiene una alteración de RET |
| EP3833372A4 (en) | 2018-08-10 | 2022-06-08 | Blueprint Medicines Corporation | TREATMENT OF EGFR MUTANT CANCER |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| KR102850357B1 (ko) | 2018-10-22 | 2025-08-27 | 알루미스 인크. | Tyk2 억제제 및 이의 용도 |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| BR112021025786A2 (pt) | 2019-06-19 | 2022-02-01 | Turning Point Therapeutics Inc | Polimorfos de um inibidor de quinase macrocíclico |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| MX2022006853A (es) * | 2019-12-03 | 2022-09-19 | Turning Point Therapeutics Inc | Macrociclos para uso en el tratamiento de enfermedades. |
| IL298523A (en) | 2020-05-29 | 2023-01-01 | Blueprint Medicines Corp | Solid forms of perletinib |
| EP4163283A1 (en) | 2020-06-04 | 2023-04-12 | Scinnohub Pharmaceutical Co., Ltd | Compound having macrocyclic structure and use thereof |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED DEGRADATION OF RET |
| WO2023060022A1 (en) * | 2021-10-05 | 2023-04-13 | Turning Point Therapeutics, Inc. | Synthesis of macrocyclic compounds |
| WO2024017380A1 (zh) * | 2022-07-22 | 2024-01-25 | 南京明德新药研发有限公司 | 含三并环的大环类化合物及其应用 |
| JP2025528836A (ja) * | 2022-08-17 | 2025-09-02 | ツリーライン バイオサイエンシズ インコーポレイテッド | ピリドピリミジンＫＲａｓ阻害剤 |
| JP7571173B2 (ja) | 2023-02-24 | 2024-10-22 | キヤノン株式会社 | 撮像装置、撮像装置の制御方法、及びプログラム |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3298885B2 (ja) * | 1993-03-25 | 2002-07-08 | ファルマシア・アンド・アップジョン・カンパニー | ドーパミン作働性活性を有するインドールテトラリン類 |
| SG63570A1 (en) | 1993-12-07 | 1999-03-30 | Lilly Co Eli | Protein kinase c inhibitors |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| MXPA03005139A (es) | 2000-12-08 | 2004-01-29 | Ortho Mcneil Pharm Inc | Compuestos macroheterociclicos utiles como inhibidores de cinasa. |
| US8815872B2 (en) | 2008-09-08 | 2014-08-26 | Merck Patent Gmbh | Macrocyclics pyrimidines as aurora kinase inhibitors |
| CN103965200B (zh) | 2008-09-22 | 2016-06-08 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
| CN102264736B (zh) | 2008-10-22 | 2013-08-14 | 阵列生物制药公司 | 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| WO2010051549A1 (en) | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| ES2446720T3 (es) | 2009-10-13 | 2014-03-10 | Elanco Animal Health Ireland Limited | Inhibidores de la integrasa macrocíclica |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| EP3521291A1 (en) | 2010-05-20 | 2019-08-07 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| CA2817785A1 (en) * | 2010-11-19 | 2012-05-24 | Toby Blench | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| MX2014001945A (es) | 2011-08-19 | 2014-03-27 | Merck Sharp & Dohme | Procedimiento e intermedios para la preparacion de macrolactamas. |
| CA2849999A1 (en) | 2011-09-30 | 2013-04-04 | Oncodesign S.A. | Macrocyclic flt3 kinase inhibitors |
| CA2863892C (en) | 2012-03-06 | 2016-08-30 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| BR112014022271B1 (pt) | 2012-03-09 | 2021-09-21 | Lexicon Pharmaceuticals, Inc | Compostos com base em imidazo[1,2-b]piridazina, composições compreendendo-os, e usos dos mesmos |
| EP2834243B1 (en) | 2012-03-09 | 2018-04-25 | Lexicon Pharmaceuticals, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| RS65417B1 (sr) * | 2014-01-24 | 2024-05-31 | Turning Point Therapeutics Inc | Diaril makrocikli kao modulatori protein kinaza |
| DK3172213T3 (da) * | 2014-07-21 | 2021-12-13 | Dana Farber Cancer Inst Inc | Makrocykliske kinasehæmmere og anvendelser deraf |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| MX386680B (es) | 2015-07-06 | 2025-03-19 | Turning Point Therapeutics Inc | Polimorfo de macrociclo de diarilo. |
| HUE070316T2 (hu) | 2015-07-21 | 2025-05-28 | Turning Point Therapeutics Inc | Királis diaril makrociklus és annak felhasználása rák kezelésében |
| ES2812336T3 (es) * | 2016-03-03 | 2021-03-16 | Shenzhen Targetrx Inc | Macrocíclico y composición que comprende el mismo |
| CN106008531B (zh) * | 2016-05-30 | 2019-01-11 | 上海交通大学 | 多环稠合大环内酰胺类化合物的抗胰腺癌用途 |
| WO2018022911A1 (en) | 2016-07-28 | 2018-02-01 | Tp Therapeutics, Inc. | Macrocycle kinase inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| SI3658148T1 (sl) | 2017-07-28 | 2024-10-30 | Turning Point Therapeutics, Inc. | Makrociklične spojine in njihova uporaba |
| SMT202100656T1 (it) | 2017-10-18 | 2022-01-10 | Incyte Corp | Derivati di imidazolo condensati sostituiti con gruppi ossidrile terziari come inibitori di pi3k-gamma |
| HRP20211918T8 (hr) | 2017-12-19 | 2022-04-15 | Bristol-Myers Squibb Company | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti |
| PE20200937A1 (es) | 2017-12-19 | 2020-09-17 | Turning Point Therapeutics Inc | Compuestos macrociclicos para tratar enfermedades |
| EP3728270A4 (en) * | 2017-12-19 | 2021-06-23 | Turning Point Therapeutics, Inc. | MACROCYCLIC KINASE INHIBITORS AND THEIR USES |
| GB201721235D0 (en) | 2017-12-19 | 2018-01-31 | Syngenta Participations Ag | Polymorphs |
| CN109956957B (zh) | 2017-12-22 | 2021-11-09 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| JP7094438B2 (ja) | 2018-04-18 | 2022-07-01 | ヒットジェン・インコーポレーテッド | 大環状キナーゼ阻害剤 |
-
2018
- 2018-12-18 PE PE2020000787A patent/PE20200937A1/es unknown
- 2018-12-18 CN CN201880082563.6A patent/CN111511746B/zh active Active
- 2018-12-18 SI SI201830779T patent/SI3728271T1/sl unknown
- 2018-12-18 WO PCT/US2018/066158 patent/WO2019126121A1/en not_active Ceased
- 2018-12-18 PT PT188932933T patent/PT3728271T/pt unknown
- 2018-12-18 KR KR1020207017739A patent/KR102814342B1/ko active Active
- 2018-12-18 MX MX2020006490A patent/MX2020006490A/es unknown
- 2018-12-18 PL PL18893293.3T patent/PL3728271T3/pl unknown
- 2018-12-18 DK DK18893293.3T patent/DK3728271T3/da active
- 2018-12-18 HU HUE18893293A patent/HUE060711T2/hu unknown
- 2018-12-18 ES ES18893293T patent/ES2929467T3/es active Active
- 2018-12-18 EP EP22191652.1A patent/EP4151641A1/en active Pending
- 2018-12-18 CA CA3083674A patent/CA3083674A1/en active Pending
- 2018-12-18 RS RS20221099A patent/RS63787B1/sr unknown
- 2018-12-18 LT LTEPPCT/US2018/066158T patent/LT3728271T/lt unknown
- 2018-12-18 JP JP2020533594A patent/JP7194188B2/ja active Active
- 2018-12-18 HR HRP20221502TT patent/HRP20221502T1/hr unknown
- 2018-12-18 JO JOP/2020/0152A patent/JOP20200152A1/ar unknown
- 2018-12-18 SG SG11202005590PA patent/SG11202005590PA/en unknown
- 2018-12-18 EP EP18893293.3A patent/EP3728271B1/en active Active
- 2018-12-18 SM SM20220443T patent/SMT202200443T1/it unknown
- 2018-12-18 AU AU2018392332A patent/AU2018392332B2/en not_active Ceased
- 2018-12-18 BR BR112020012319-6A patent/BR112020012319A2/pt unknown
- 2018-12-19 TW TW107145927A patent/TW201930312A/zh unknown
-
2020
- 2020-01-30 US US16/777,717 patent/US10745416B2/en active Active
- 2020-05-05 US US16/866,983 patent/US11286265B2/en active Active
- 2020-06-10 IL IL275265A patent/IL275265B2/en unknown
- 2020-06-15 PH PH12020550901A patent/PH12020550901A1/en unknown
- 2020-06-17 CL CL2020001632A patent/CL2020001632A1/es unknown
- 2020-06-19 EC ECSENADI202033467A patent/ECSP20033467A/es unknown
-
2022
- 2022-02-14 US US17/670,665 patent/US20220306652A1/en not_active Abandoned
- 2022-12-09 JP JP2022197141A patent/JP2023027237A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3728271T3 (da) | Makrocykliske forbindelser til behandling af sygdomme | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3245206T3 (da) | Pyrazinforbindelser til behandling af infektionssygdomme | |
| DK3173092T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3785733T3 (da) | Farmaceutisk sammensætning til behandling af autisme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3439635T3 (da) | Formuleringer til behandling af fast tumor | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme | |
| DK3400072T3 (da) | Formuleringer til behandling af blærecancer | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3638293T5 (da) | Sammensætninger til behandling af cancer |